JP6272897B2 - Ｃｘｃｒ７アンタゴニスト - Google Patents
Ｃｘｃｒ７アンタゴニスト Download PDFInfo
- Publication number
- JP6272897B2 JP6272897B2 JP2015545194A JP2015545194A JP6272897B2 JP 6272897 B2 JP6272897 B2 JP 6272897B2 JP 2015545194 A JP2015545194 A JP 2015545194A JP 2015545194 A JP2015545194 A JP 2015545194A JP 6272897 B2 JP6272897 B2 JP 6272897B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- pyrazin
- mixture
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*C(*1)**(*)C1C1CCCC1 Chemical compound C*C(*1)**(*)C1C1CCCC1 0.000 description 6
- ORAXRJZMNYAONE-QMMMGPOBSA-N N[C@@H](CC1)CN1c1ncc[n]2c1ncc2 Chemical compound N[C@@H](CC1)CN1c1ncc[n]2c1ncc2 ORAXRJZMNYAONE-QMMMGPOBSA-N 0.000 description 2
- ACFQGTMTFLDFLP-UHFFFAOYSA-N OC(c(nc1)n[n]1-c1ccccc1)=O Chemical compound OC(c(nc1)n[n]1-c1ccccc1)=O ACFQGTMTFLDFLP-UHFFFAOYSA-N 0.000 description 2
- OKXMGVHRDZMSHD-UHFFFAOYSA-N CC(C)(C)OC(NC(CC1)CN1c1ncc[n]2c1ncc2)=O Chemical compound CC(C)(C)OC(NC(CC1)CN1c1ncc[n]2c1ncc2)=O OKXMGVHRDZMSHD-UHFFFAOYSA-N 0.000 description 1
- OVCZWYWPEURLLC-NKUHCKNESA-N CC(C)(C)OC(N[C@@H](CC1)CN1c1ncc[n]2c1nnc2)O Chemical compound CC(C)(C)OC(N[C@@H](CC1)CN1c1ncc[n]2c1nnc2)O OVCZWYWPEURLLC-NKUHCKNESA-N 0.000 description 1
- QBUYSZVLLXERPF-HNNXBMFYSA-N CC(c1cnc(C(N[C@@H](CC2)CN2c2ncc[n]3c2ccc3)=O)nc1)=C Chemical compound CC(c1cnc(C(N[C@@H](CC2)CN2c2ncc[n]3c2ccc3)=O)nc1)=C QBUYSZVLLXERPF-HNNXBMFYSA-N 0.000 description 1
- ZKFYNORVXMUKJL-UHFFFAOYSA-N CCOC(c(cc1)n[n]1-c1cc(F)ccc1)=O Chemical compound CCOC(c(cc1)n[n]1-c1cc(F)ccc1)=O ZKFYNORVXMUKJL-UHFFFAOYSA-N 0.000 description 1
- SZAZXQCELZVSPX-UHFFFAOYSA-N CCOC(c(nc1)n[n]1-c(cc1)ccc1F)=O Chemical compound CCOC(c(nc1)n[n]1-c(cc1)ccc1F)=O SZAZXQCELZVSPX-UHFFFAOYSA-N 0.000 description 1
- JGTVQPDBVWPOTM-ZDUSSCGKSA-N CN(C)c1cnc(C(N[C@@H](CC2)CN2c2ncc[n]3c2ccc3)=O)nc1 Chemical compound CN(C)c1cnc(C(N[C@@H](CC2)CN2c2ncc[n]3c2ccc3)=O)nc1 JGTVQPDBVWPOTM-ZDUSSCGKSA-N 0.000 description 1
- XTUVJUMINZSXGF-UHFFFAOYSA-N CNC1CCCCC1 Chemical compound CNC1CCCCC1 XTUVJUMINZSXGF-UHFFFAOYSA-N 0.000 description 1
- KAWPQMMOZTUKLK-JTQLQIEISA-N Cc(cc1)c2[n]1ccnc2N(CC1)C[C@H]1N Chemical compound Cc(cc1)c2[n]1ccnc2N(CC1)C[C@H]1N KAWPQMMOZTUKLK-JTQLQIEISA-N 0.000 description 1
- IKOSMPDLTAPQPT-KRWDZBQOSA-N Cc(cc1)c2[n]1ccnc2N(CC1)C[C@H]1NC(c(cc1)n[n]1-c(cc1)ccc1Cl)=O Chemical compound Cc(cc1)c2[n]1ccnc2N(CC1)C[C@H]1NC(c(cc1)n[n]1-c(cc1)ccc1Cl)=O IKOSMPDLTAPQPT-KRWDZBQOSA-N 0.000 description 1
- CWSBNFQIWWIIPG-INIZCTEOSA-N Cc(cccc1)c1-[n]1nc(C(N[C@@H](CC2)CN2c2ncc[n]3c2ccc3)=O)nc1 Chemical compound Cc(cccc1)c1-[n]1nc(C(N[C@@H](CC2)CN2c2ncc[n]3c2ccc3)=O)nc1 CWSBNFQIWWIIPG-INIZCTEOSA-N 0.000 description 1
- KOVQMQWLQDYPAR-UHFFFAOYSA-N Cc(cccc1)c1-[n]1nc(C(O)=O)nc1 Chemical compound Cc(cccc1)c1-[n]1nc(C(O)=O)nc1 KOVQMQWLQDYPAR-UHFFFAOYSA-N 0.000 description 1
- RINOYHWVBUKAQE-UHFFFAOYSA-N Cc(cccc1)c1I Chemical compound Cc(cccc1)c1I RINOYHWVBUKAQE-UHFFFAOYSA-N 0.000 description 1
- DBUFGLULXNKLMX-UHFFFAOYSA-N Cc1ccccc1-[n](cc1)nc1C(O)=O Chemical compound Cc1ccccc1-[n](cc1)nc1C(O)=O DBUFGLULXNKLMX-UHFFFAOYSA-N 0.000 description 1
- RIACGZKDDNFQAZ-MFKUBSTISA-N Cc1nc(C(/N=C(\CC2)/CN2c2ncc[n]3c2ncc3)=O)n[n]1-c(cc1)ccc1F Chemical compound Cc1nc(C(/N=C(\CC2)/CN2c2ncc[n]3c2ncc3)=O)n[n]1-c(cc1)ccc1F RIACGZKDDNFQAZ-MFKUBSTISA-N 0.000 description 1
- IOKWGFCAXYAKKM-UHFFFAOYSA-O Cc1nc(C(O)=[OH+])n[n]1-c(cc1)ccc1F Chemical compound Cc1nc(C(O)=[OH+])n[n]1-c(cc1)ccc1F IOKWGFCAXYAKKM-UHFFFAOYSA-O 0.000 description 1
- VKZJRJVVFDDJKP-UHFFFAOYSA-N Clc1ncc[n]2c1nnc2 Chemical compound Clc1ncc[n]2c1nnc2 VKZJRJVVFDDJKP-UHFFFAOYSA-N 0.000 description 1
- ORAXRJZMNYAONE-UHFFFAOYSA-N NC(CC1)CN1c1ncc[n]2c1ncc2 Chemical compound NC(CC1)CN1c1ncc[n]2c1ncc2 ORAXRJZMNYAONE-UHFFFAOYSA-N 0.000 description 1
- ANJGIBWJJBJIAD-UHFFFAOYSA-N NC(CO)(CC1)CN1c1ncc[n]2c1ccc2 Chemical compound NC(CO)(CC1)CN1c1ncc[n]2c1ccc2 ANJGIBWJJBJIAD-UHFFFAOYSA-N 0.000 description 1
- QJAWHSQGWANHCM-VIFPVBQESA-N N[C@@H](CC1)CN1c1ncc[n]2c1ccc2 Chemical compound N[C@@H](CC1)CN1c1ncc[n]2c1ccc2 QJAWHSQGWANHCM-VIFPVBQESA-N 0.000 description 1
- RLXREJLLZLVGGK-ZETCQYMHSA-N N[C@@H](CC1)CN1c1ncc[n]2c1nnc2 Chemical compound N[C@@H](CC1)CN1c1ncc[n]2c1nnc2 RLXREJLLZLVGGK-ZETCQYMHSA-N 0.000 description 1
- UEPSPNNKZCKUHL-QMMMGPOBSA-N N[C@@H](CC1)CN1c1ncc[n]2nccc12 Chemical compound N[C@@H](CC1)CN1c1ncc[n]2nccc12 UEPSPNNKZCKUHL-QMMMGPOBSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N Nc(cc1)ccc1F Chemical compound Nc(cc1)ccc1F KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- SZHWWRBGKDDSQB-HNNXBMFYSA-N O=C(C(NC1)=Nc(cc2)c1cc2Cl)N[C@@H](CC1)CN1c1ncc[n]2c1ccc2 Chemical compound O=C(C(NC1)=Nc(cc2)c1cc2Cl)N[C@@H](CC1)CN1c1ncc[n]2c1ccc2 SZHWWRBGKDDSQB-HNNXBMFYSA-N 0.000 description 1
- BCVPXOUVJAUWAN-UHFFFAOYSA-N O=C(c(nc1)n[n]1-c(cc1)ccc1F)Cl Chemical compound O=C(c(nc1)n[n]1-c(cc1)ccc1F)Cl BCVPXOUVJAUWAN-UHFFFAOYSA-N 0.000 description 1
- MDEPQPNGXJIOOB-HNNXBMFYSA-N O=C(c(nc1)n[n]1-c(cc1)ccc1F)N[C@@H](CC1)CN1c1ncc[n]2c1ccc2 Chemical compound O=C(c(nc1)n[n]1-c(cc1)ccc1F)N[C@@H](CC1)CN1c1ncc[n]2c1ccc2 MDEPQPNGXJIOOB-HNNXBMFYSA-N 0.000 description 1
- QPEDKZAZXMYGPX-UHFFFAOYSA-N O=C(c(nc1)n[n]1-c1ccccc1)NC(CC1)CN1c1ncc[n]2c1nnc2 Chemical compound O=C(c(nc1)n[n]1-c1ccccc1)NC(CC1)CN1c1ncc[n]2c1nnc2 QPEDKZAZXMYGPX-UHFFFAOYSA-N 0.000 description 1
- ONIMSZJFFFNZHA-AWEZNQCLSA-N O=C(c(nc1)n[n]1-c1ccccc1)N[C@@H](CC1)CN1c1ncc[n]2c1ncc2 Chemical compound O=C(c(nc1)n[n]1-c1ccccc1)N[C@@H](CC1)CN1c1ncc[n]2c1ncc2 ONIMSZJFFFNZHA-AWEZNQCLSA-N 0.000 description 1
- AKCMHEJMXOCHOG-LBPRGKRZSA-N O=C(c(nc1)ncc1Br)N[C@@H](CC1)CN1c1ncc[n]2c1ccc2 Chemical compound O=C(c(nc1)ncc1Br)N[C@@H](CC1)CN1c1ncc[n]2c1ccc2 AKCMHEJMXOCHOG-LBPRGKRZSA-N 0.000 description 1
- LVHIVLYJQXXIIN-HNNXBMFYSA-N O=C(c1c[s]c(-c2ccccc2)n1)N[C@@H](CC1)CN1c1ncc[n]2c1ncc2 Chemical compound O=C(c1c[s]c(-c2ccccc2)n1)N[C@@H](CC1)CN1c1ncc[n]2c1ncc2 LVHIVLYJQXXIIN-HNNXBMFYSA-N 0.000 description 1
- XYJQPNTYSQYYTE-ZDUSSCGKSA-N O=C(c1n[n](-c2ccccc2)nn1)N[C@@H](CC1)CN1c1ncc[n]2c1ncc2 Chemical compound O=C(c1n[n](-c2ccccc2)nn1)N[C@@H](CC1)CN1c1ncc[n]2c1ncc2 XYJQPNTYSQYYTE-ZDUSSCGKSA-N 0.000 description 1
- OYGSDSZQKGMLJZ-UHFFFAOYSA-N OC(c(cc1)n[n]1-c(cc1)ccc1F)=O Chemical compound OC(c(cc1)n[n]1-c(cc1)ccc1F)=O OYGSDSZQKGMLJZ-UHFFFAOYSA-N 0.000 description 1
- AXDRYXSIVKHKKA-UHFFFAOYSA-N OC(c(cc1)n[n]1-c1cccc(F)c1)=O Chemical compound OC(c(cc1)n[n]1-c1cccc(F)c1)=O AXDRYXSIVKHKKA-UHFFFAOYSA-N 0.000 description 1
- IBUSLNJQKLZPNR-UHFFFAOYSA-N OC(c1c[s]c(-c2ccccc2)n1)=O Chemical compound OC(c1c[s]c(-c2ccccc2)n1)=O IBUSLNJQKLZPNR-UHFFFAOYSA-N 0.000 description 1
- WXQANAHPYDUEQX-DIMJTDRSSA-N OCCC([C@@H](CC1)CN1c1ncc[n]2c1ccc2)NC(c(cc1)n[n]1-c(cc1)ccc1F)=O Chemical compound OCCC([C@@H](CC1)CN1c1ncc[n]2c1ccc2)NC(c(cc1)n[n]1-c(cc1)ccc1F)=O WXQANAHPYDUEQX-DIMJTDRSSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261731463P | 2012-11-29 | 2012-11-29 | |
| US61/731,463 | 2012-11-29 | ||
| PCT/US2013/072067 WO2014085490A1 (en) | 2012-11-29 | 2013-11-26 | Cxcr7 antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016502538A JP2016502538A (ja) | 2016-01-28 |
| JP2016502538A5 JP2016502538A5 (https=) | 2016-12-22 |
| JP6272897B2 true JP6272897B2 (ja) | 2018-01-31 |
Family
ID=50825654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545194A Active JP6272897B2 (ja) | 2012-11-29 | 2013-11-26 | Ｃｘｃｒ７アンタゴニスト |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US9169261B2 (https=) |
| EP (1) | EP2925745B1 (https=) |
| JP (1) | JP6272897B2 (https=) |
| KR (1) | KR102196374B1 (https=) |
| CN (1) | CN105189484B (https=) |
| AU (1) | AU2013352304C1 (https=) |
| BR (1) | BR112015012366A8 (https=) |
| CA (1) | CA2892042C (https=) |
| DK (1) | DK2925745T3 (https=) |
| ES (1) | ES2681593T3 (https=) |
| IL (1) | IL238974B (https=) |
| MX (1) | MX359651B (https=) |
| PT (1) | PT2925745T (https=) |
| RU (1) | RU2649004C2 (https=) |
| SG (1) | SG11201504212WA (https=) |
| WO (1) | WO2014085490A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX359651B (es) | 2012-11-29 | 2018-10-05 | Chemocentryx Inc | Antagonistas de cxcr7. |
| WO2016040508A1 (en) * | 2014-09-10 | 2016-03-17 | Epizyme, Inc. | Substituted pyrrolidine carboxamide compounds |
| BR112017018119B1 (pt) | 2015-02-24 | 2021-11-03 | Bayer Cropscience Aktiengesellschaft | Processo para a preparação de triazóis |
| EP4302834A3 (en) | 2016-07-12 | 2024-07-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| MA45782B1 (fr) * | 2016-07-28 | 2021-12-31 | Idorsia Pharmaceuticals Ltd | Modulateurs du récepteur de cxcr7 pipéridine |
| KR20190110588A (ko) | 2017-01-23 | 2019-09-30 | 레볼루션 메디슨즈, 인크. | 알로스테릭 shp2 억제제로서의 피리딘 화합물 |
| JP7240319B2 (ja) * | 2017-01-23 | 2023-03-15 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての二環式化合物 |
| CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| TW201930292A (zh) | 2017-10-12 | 2019-08-01 | 美商銳新醫藥公司 | 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物 |
| EP3713934B1 (en) | 2017-11-23 | 2022-04-13 | Universita' degli Studi di Palermo | Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations |
| JP7361693B2 (ja) | 2017-12-15 | 2023-10-16 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての多環式化合物 |
| WO2019145460A1 (en) * | 2018-01-26 | 2019-08-01 | Idorsia Pharmaceuticals Ltd | Crystalline forms of the cxcr7 receptor antagonist (3s,4s)-1-cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide |
| CN108794484B (zh) * | 2018-04-28 | 2020-04-24 | 北京施安泰医药技术开发有限公司 | [1,2,4]三唑并[4,3-a]吡嗪衍生物、其药物组合物、制备方法和应用 |
| MX2021006915A (es) | 2018-12-12 | 2021-08-24 | Chemocentryx Inc | Inhibidores de cxcr7 para el tratamiento de cancer. |
| CN110013483B (zh) * | 2019-05-10 | 2022-04-15 | 江苏师范大学 | 噻唑并[3,2-a]嘧啶-6-甲腈衍生物用于抗菌的用途 |
| BR112021025888A2 (pt) | 2019-07-10 | 2022-04-26 | Chemocentryx Inc | Indanos como inibidores de pd-l1 |
| ES3064674T3 (en) | 2019-10-16 | 2026-04-28 | Chemocentryx Inc | Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases |
| JP7736678B2 (ja) | 2019-10-16 | 2025-09-09 | ケモセントリックス，インコーポレイティド | Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド |
| TWI879949B (zh) | 2020-04-27 | 2025-04-11 | 南韓商奧土擇破利悟股份有限公司 | 用於ｕｂｒ盒結構域配體之化合物、組成物以及醫藥組成物 |
| CN113105469B (zh) * | 2021-04-13 | 2022-04-22 | 中国科学院新疆理化技术研究所 | 一种三环呋喃并[2,3-d]嘧啶酮类化合物及用途 |
| EP4326257A4 (en) * | 2021-04-19 | 2025-03-12 | ChemoCentryx, Inc. | AZETIDINYLACETAMIDES AS CXCR7 INHIBITORS |
| WO2024042480A1 (en) | 2022-08-26 | 2024-02-29 | Suven Life Sciences Limited | Heteroaromatic compounds for the treatment of neurological disorders |
| PY24116080A (es) | 2024-01-03 | 2025-08-04 | Pi Industries Ltd | Amidas heterociclicas biciclicas para combatir hongos fitopatógenos |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4966691A (https=) | 1972-10-30 | 1974-06-27 | ||
| JP3989554B2 (ja) | 1996-03-29 | 2007-10-10 | デユフアー・インターナシヨナル・リサーチ・ベー・ブイ | ピペラジンおよびピペリジン化合物 |
| ES2215420T3 (es) * | 1998-12-31 | 2004-10-01 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Inhibidores de la prenil-transferasa. |
| DE60007745T2 (de) * | 1999-06-30 | 2005-03-10 | Bristol-Myers Squibb Co. | Heterocyclische aminopyrrolidon-derivate als melatonergene wirkstoffe |
| EP1301484A2 (en) | 2000-07-20 | 2003-04-16 | Neurogen Corporation | Capsaicin receptor ligands |
| ME00502B (me) | 2001-01-05 | 2011-10-10 | Amgen Fremont Inc | Antitjela za insulinu sličan receptor faktora i rasta |
| CA2448080A1 (en) | 2001-05-22 | 2002-11-28 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
| US7169750B2 (en) * | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
| US7871619B2 (en) | 2001-11-30 | 2011-01-18 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| MXPA04008797A (es) | 2002-03-13 | 2004-11-26 | Janssen Pharmaceutica Nv | Inhibidores de histona desacetilasa. |
| WO2004009587A1 (en) | 2002-07-22 | 2004-01-29 | Orchid Chemicals & Pharmaceuticals Ltd | Oxazolidinone derivatives as antibacterial agents |
| JP2004203871A (ja) | 2002-12-13 | 2004-07-22 | Yamanouchi Pharmaceut Co Ltd | 医薬組成物 |
| WO2005023771A1 (ja) | 2003-09-05 | 2005-03-17 | Ono Pharmaceutical Co., Ltd. | ケモカインレセプターアンタゴニストおよびその医薬用途 |
| WO2005074535A2 (en) | 2004-01-30 | 2005-08-18 | Eisai Co., Ltd. | Cholinesterase inhibitors for spinal cord disorders |
| WO2005074645A2 (en) | 2004-02-03 | 2005-08-18 | Chemocentryx, Inc. | Methods and compositions for modulating angiogenesis |
| AU2006230674A1 (en) | 2004-03-18 | 2006-11-16 | The Brigham And Women's Hospital, Inc. | Methods for the Treatment of Synucleinopathies |
| EP1637529A1 (en) | 2004-09-20 | 2006-03-22 | 4Sc Ag | Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof |
| US7601745B2 (en) | 2004-09-27 | 2009-10-13 | 4Sc Ag | Heterocyclic NF-kB inhibitors |
| WO2006038989A1 (en) * | 2004-09-29 | 2006-04-13 | Chemocentryx, Inc. | Substituted arylamides |
| WO2006100461A1 (en) | 2005-03-23 | 2006-09-28 | Astrazeneca Ab | 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY |
| AU2006263657A1 (en) * | 2005-06-29 | 2007-01-04 | Chemocentryx, Inc. | Substituted N-cinnamyl benzamides |
| DK1954274T3 (da) * | 2005-11-10 | 2011-01-31 | Chemocentryx Inc | Substituerede quinoloner og fremgangsmåder til anvendelse |
| WO2007111275A1 (ja) | 2006-03-24 | 2007-10-04 | The University Of Tokyo | シグナル伝達阻害方法、それに用いるシグナル伝達阻害剤およびその用途 |
| EP2001485B1 (en) | 2006-03-29 | 2015-09-09 | Merck Sharp & Dohme Corp. | Diazepan orexin receptor antagonists |
| WO2007115232A2 (en) | 2006-03-30 | 2007-10-11 | Chemocentryx, Inc. | Cxcr4 modulators |
| WO2007115231A2 (en) | 2006-03-30 | 2007-10-11 | Chemocentryx, Inc. | Cxcr4 modulators |
| US20090192143A1 (en) | 2006-07-14 | 2009-07-30 | Cox Christopher D | Substituted diazepan orexin receptor antagonists |
| BRPI0714440A2 (pt) | 2006-07-21 | 2013-04-24 | Irm Llc | composto inibidor de itpkb, uso do mesmo e composiÇço farmacÊutica |
| WO2008020229A2 (en) * | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Antibacterial pyrrolecarboxamides |
| US8088895B2 (en) * | 2006-10-18 | 2012-01-03 | Chemocentryx, Inc. | Antibodies that bind CXCR7 epitopes |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| KR20090094125A (ko) | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| AR064464A1 (es) | 2006-12-22 | 2009-04-01 | Genentech Inc | Anticuerpos anti - receptor del factor de crecimiento insulinico |
| US20080293711A1 (en) | 2007-03-08 | 2008-11-27 | Clark Michael P | Chemokine receptor modulators |
| TW200944523A (en) | 2008-02-08 | 2009-11-01 | Organon Nv | (Dihydro)pyrrolo[2,1-a]isoquinolines |
| CA2742515C (en) | 2008-11-04 | 2017-07-11 | Chemocentryx, Inc. | 1,4-diazepane modulators of cxcr7 |
| US8853202B2 (en) | 2008-11-04 | 2014-10-07 | Chemocentryx, Inc. | Modulators of CXCR7 |
| US20110014121A1 (en) | 2008-11-04 | 2011-01-20 | Chemocentryx, Inc. | Modulators of cxcr7 |
| GB0822981D0 (en) * | 2008-12-17 | 2009-01-21 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| KR101541086B1 (ko) * | 2010-08-20 | 2015-08-03 | 허치슨 메디파르마 리미티드 | 피롤로피리미딘 화합물 및 그 용도 |
| CN102372717B (zh) * | 2010-08-20 | 2014-06-18 | 和记黄埔医药（上海）有限公司 | 吡咯并嘧啶类化合物及其用途 |
| EP2616442B8 (en) | 2010-09-14 | 2018-10-17 | Exelixis, Inc. | Inhibitors of pi3k-delta and methods of their use and manufacture |
| GB201017345D0 (en) | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
| US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
| AU2012245971A1 (en) | 2011-04-21 | 2013-10-17 | Piramal Enterprises Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| MX359651B (es) | 2012-11-29 | 2018-10-05 | Chemocentryx Inc | Antagonistas de cxcr7. |
| US9260527B2 (en) | 2013-03-15 | 2016-02-16 | Sdix, Llc | Anti-human CXCR4 antibodies and methods of making same |
| MX2021006915A (es) | 2018-12-12 | 2021-08-24 | Chemocentryx Inc | Inhibidores de cxcr7 para el tratamiento de cancer. |
-
2013
- 2013-11-26 MX MX2015006412A patent/MX359651B/es active IP Right Grant
- 2013-11-26 CA CA2892042A patent/CA2892042C/en active Active
- 2013-11-26 KR KR1020157017200A patent/KR102196374B1/ko active Active
- 2013-11-26 WO PCT/US2013/072067 patent/WO2014085490A1/en not_active Ceased
- 2013-11-26 ES ES13859147.4T patent/ES2681593T3/es active Active
- 2013-11-26 AU AU2013352304A patent/AU2013352304C1/en active Active
- 2013-11-26 BR BR112015012366A patent/BR112015012366A8/pt not_active Application Discontinuation
- 2013-11-26 CN CN201380062708.3A patent/CN105189484B/zh active Active
- 2013-11-26 RU RU2015125544A patent/RU2649004C2/ru active
- 2013-11-26 DK DK13859147.4T patent/DK2925745T3/en active
- 2013-11-26 PT PT138591474T patent/PT2925745T/pt unknown
- 2013-11-26 SG SG11201504212WA patent/SG11201504212WA/en unknown
- 2013-11-26 JP JP2015545194A patent/JP6272897B2/ja active Active
- 2013-11-26 EP EP13859147.4A patent/EP2925745B1/en active Active
- 2013-11-27 US US14/091,641 patent/US9169261B2/en active Active
-
2015
- 2015-05-21 IL IL238974A patent/IL238974B/en active IP Right Grant
- 2015-08-26 US US14/836,172 patent/US9783544B2/en active Active
-
2017
- 2017-08-31 US US15/692,739 patent/US10287292B2/en active Active
-
2019
- 2019-04-09 US US16/379,599 patent/US11059825B2/en active Active
-
2021
- 2021-05-27 US US17/331,750 patent/US11834452B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6272897B2 (ja) | Ｃｘｃｒ７アンタゴニスト | |
| JP5785089B2 (ja) | Ｃｘｃｒ７の調節因子 | |
| US8853202B2 (en) | Modulators of CXCR7 | |
| HK1214264B (en) | Cxcr7 antagonists | |
| US20110014121A1 (en) | Modulators of cxcr7 | |
| TW202309016A (zh) | 作為cxcr7抑制劑之吖丁啶基-乙醯胺 | |
| AU2009313558B9 (en) | Modulators of CXCR7 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161101 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161101 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170829 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170831 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171128 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171205 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180104 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6272897 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |